Ganesh Prasanna

ORCID: 0000-0001-6420-270X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glaucoma and retinal disorders
  • Nitric Oxide and Endothelin Effects
  • Retinal Diseases and Treatments
  • Retinal Development and Disorders
  • Neurological Disorders and Treatments
  • Retinal Imaging and Analysis
  • Proteoglycans and glycosaminoglycans research
  • Connexins and lens biology
  • Ocular Surface and Contact Lens
  • Inflammatory mediators and NSAID effects
  • Retinal and Optic Conditions
  • Corneal surgery and disorders
  • Protein Kinase Regulation and GTPase Signaling
  • Protease and Inhibitor Mechanisms
  • Retinopathy of Prematurity Studies
  • Ophthalmology and Eye Disorders
  • Photoreceptor and optogenetics research
  • Biochemical effects in animals
  • Corneal Surgery and Treatments
  • Calpain Protease Function and Regulation
  • Biomedical Research and Pathophysiology
  • Ocular Infections and Treatments
  • Circadian rhythm and melatonin
  • Barrier Structure and Function Studies
  • Blood Coagulation and Thrombosis Mechanisms

Novartis (United States)
2013-2025

Boston Biomedical Research Institute
2024

University of Oklahoma Health Sciences Center
2024

Novartis (China)
2024

Neurogen Brain & Spine Institute
2024

All India Institute of Medical Sciences Bhubaneswar
2022

Glaucoma Research Foundation
2013-2016

Pfizer (United States)
2005-2015

University of North Texas Health Science Center
2000-2013

University of North Texas
2000-2013

Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular aqueous humor dynamics by targeting mechanisms that are complementary to those prostaglandins. Here, we have characterized newly synthesized compound, NCX 125, comprising latanoprost acid and NO-donating moieties. Methods: 125 was tested vitro for its ability release functionally active NO then compared with core intraocular pressure (IOP)-lowering effects rabbit, dog, nonhuman primate models...

10.1089/jop.2009.0120 article EN Journal of Ocular Pharmacology and Therapeutics 2010-04-01

Neurodegeneration in glaucoma patients is clinically identified through longitudinal assessment of structure–function changes, including intraocular pressure, cup-to-disc ratios from fundus images, and optical coherence tomography imaging the retinal nerve fiber layer. Use human post-mortem ocular tissue for basic research rising field, yet there are challenges assessing disease stage severity, since donations with informed consent often unaccompanied by detailed pre-mortem clinical...

10.1186/s40478-024-01880-2 article EN cc-by-nc-nd Acta Neuropathologica Communications 2025-01-06

Endothelin (ET)-1 levels are increased in aqueous and vitreous humor patients with glaucoma animal models of glaucoma. Whether the elevated ET-1 induces extracellular matrix (ECM) remodeling optic nerve head is still unknown. In present study, regulation metalloproteinases/tissue inhibitors metalloproteinases (MMPs/TIMPs) ECM ET-1-activated human astrocytes (hONAs) were determined.Primary hONAs exposed to for 1 day 4 days. Incubation media subjected zymography Western blot detect activity...

10.1167/iovs.06-1138 article EN Investigative Ophthalmology & Visual Science 2007-07-25

Recent observations suggest that the vasoactive peptide endothelin-1 (ET-1) may be an important contributor to etiology of glaucoma. ET-1 administration has been shown produce optic nerve axonal loss and apoptosis retinal ganglion cells. Ocular levels are elevated in aqueous humor response intraocular pressure both glaucoma patients animal models glaucoma; however, precise mechanisms by which mediates glaucomatous neuropathy not clear. Presently we report ET-1-mediated was markedly...

10.1139/y08-040 article EN Canadian Journal of Physiology and Pharmacology 2008-05-30

The prostaglandin F2alpha (PGF2α) analogue bimatoprost lowers intraocular pressure (IOP) by increasing uveoscleral outflow at doses shown to elicit redness of the eye. With aim enhance IOP-lowering effect we studied NCX 470 [(S,E)-1-((1R,2R,3S,5R)-2-((Z)-7-(ethylamino)-7-oxohept-2-enyl)-3,5-dihydroxycyclopentyl)-5-phenylpent-1-en-3-yl 6-(nitrooxy)hexanoate], a dual-acting compound combining with nitric oxide (NO) known mainly act via relaxation trabecular meshwork and Schlemm's canal.New...

10.1167/iovs.15-17190 article EN Investigative Ophthalmology & Visual Science 2015-10-12

Endothelin (ET)-1 can produce nerve damage analogous to that in optic neuropathies such as glaucoma. The precise source of endothelin the posterior segment eye remains unclear. present study was conducted determine whether retinal pigment epithelium (RPE), which helps maintain outer blood-retinal barrier, is a local for ET-1 and amount secreted by RPE be differentially regulated cholinergics cytokine TNF-alpha.Human epithelial cells (ARPE-19) were cultured either mature state (mRPE) 4 weeks,...

10.1167/iovs.03-0387 article EN Investigative Ophthalmology & Visual Science 2003-10-24

This study examines the effects of 2 Rho kinase inhibitors on intraocular pressure (IOP) and aqueous humor dynamics.IOPs New Zealand albino rabbits with ocular normotension cynomolgus macaques (nonhuman primate, NHP) chronic unilateral laser-induced glaucoma were measured at baseline periodically after a 9 a.m. dose H-1152, Y-27632, or vehicle. In separate group NHPs, flow, outflow facility, uveoscleral outflow, IOP determined treatment Y-27632 vehicle control.Decreases in found (n = 5) 6 h...

10.1089/jop.2015.0116 article EN Journal of Ocular Pharmacology and Therapeutics 2016-06-06

PURPOSE. To identify which endothelin receptor subtype is expressed and functional in the human ciliary body trabecular meshwork, tissues that regulate aqueous humor dynamics. METHODS. Immunocytochemistry was used to characterize primary culture cells of normal ocular cells. Endothelin gene expression probed with reverse transcription polymerase chain reaction (RT-PCR). Intracellular calcium ([Ca 2+ ] i) mobilization measured video image microscopy using Fura-2AM as a fluorescent probe....

10.1076/ceyr.17.1.31.5256 article EN Current Eye Research 1998-01-01
Coming Soon ...